Related Experiment Video
Updated: May 14, 2026
Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway
Published on: May 10, 2024
Luteolin attenuates diabetes-associated cognitive decline in rats
Yi Liu1, Xia Tian, Lingshan Gou
1Department of Pharmacy, Xuzhou Medical College, 84 West Huaihai Road, Xuzhou, Jiangsu 221002, China. cbpe201087@gmail.com
Abstract:
Diabetes mellitus can cause dysfunction of the central nervous system called "diabetic encephalopathy". Although various oral drugs are used to treat diabetes, they do not prevent the development of diabetes-associated cognitive decline in rats, and novel strategies for the prevention and treatment are urgently needed. Luteolin, a flavonoid isolated from Cirsium japonicum, has antioxidant, anti-inflammatory and neuroprotective activities. However, no report is available on influence of luteolin on streptozotocin-induced memory impairment. Therefore, we tested its influence against cognitive dysfunction in streptozotocin-induced diabetic rats using Morris water maze test. Nissl's staining, choline esterase (ChE) activity as marker of cholinergic function and oxidative stress were assessed in the cerebral cortex and hippocampus to evaluate the neuropathological changes and the effects of luteolin on diabetic rats. The results showed that streptozotocin-induced diabetes produced obvious neuron damage and cognitive dysfunction coupling with markedly increased oxidative stress and ChE activity in the brain. In contrast, chronic treatment with luteolin (50 and 100mg/kg) improved neuronal injury and cognitive performance by attenuating oxidative stress and ChE activity in diabetic rats. In conclusion, the present study suggested that oral supplementation of luteolin might be a potential therapeutic strategy for the treatment and/or prevention of diabetic encephalopathy.
Insights
Luteolin, a natural flavonoid, shows promise in preventing and treating diabetic encephalopathy. This study found it improved cognitive function and reduced brain damage in diabetic rats by combating oxidative stress.
Area of Science:
- Neuroscience
- Endocrinology
- Pharmacology
Background:
- Diabetes mellitus can lead to central nervous system dysfunction, known as diabetic encephalopathy.
- Current diabetes treatments do not prevent cognitive decline, necessitating new therapeutic strategies.
- Luteolin, a flavonoid, possesses known antioxidant, anti-inflammatory, and neuroprotective properties.
Purpose of the Study:
- To investigate the effects of luteolin on cognitive dysfunction in streptozotocin-induced diabetic rats.
- To evaluate luteolin's potential in preventing or treating diabetic encephalopathy.
- To assess luteolin's impact on neuropathological changes in the diabetic brain.
Main Methods:
- Induction of diabetes and cognitive impairment in rats using streptozotocin.
- Administration of luteolin (50 and 100mg/kg) for chronic treatment.
- Assessment of cognitive performance using the Morris water maze test.
- Evaluation of neuropathological changes via Nissl's staining, choline esterase activity, and oxidative stress markers in the cerebral cortex and hippocampus.
Main Results:
- Streptozotocin-induced diabetes caused significant neuronal damage and cognitive decline in rats.
- Diabetic rats exhibited increased oxidative stress and choline esterase activity in the brain.
- Luteolin treatment ameliorated neuronal injury and cognitive deficits.
- Luteolin attenuated oxidative stress and choline esterase activity in the brains of diabetic rats.
Conclusions:
- Luteolin demonstrates neuroprotective effects against diabetic encephalopathy in a rat model.
- Oral supplementation with luteolin may be a viable strategy for managing diabetic cognitive dysfunction.
- Luteolin holds potential for both the prevention and treatment of diabetic encephalopathy.
